PD-L1 was also highly expressed on APCs, including immature DCs, M1 macrophages, IFN-γ-induced M0 macrophages, and B cells in our study (Figure 3E–H), which implies that the blockade of the PD-1/PD-L1 axis in these cells might be a potential strategy to enhance anti-tumor immunity by blocking the inhibitory signaling pathway. The gene discussed is CD274; the disease is neoplasm.